Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Europe B.V.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Doctor's decision to prescribe Ribomustin and rituximab combined therapy for the treatment of relapsed or refractory indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Informed Consent Form for personal data handling signed by the program participant, authorized by the Independent Ethics Committee
Eastern Cooperative Oncology Group (ECOG) status \< 2.
Confirmed relapse or disease progression of B-cell CD20+ Non-Hodgkin's Lymphoma (lymphocytic, lymphocytoplasmocytic, follicular, marginal zone) after minimum one line of iNHL treatment
Patients with relapsed or refractory indolent B-cell Non-Hodgkin's Lymphoma with current or planned Ribomustin and rituximab combined therapy with following rituximab maintenance therapy
You may not be if
Indolent Non-Hodgkin's Lymphoma transformation
Lymphoma with central nervous system (CNS) involvement
Presence of second malignant tumor.
Currently participating in any clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment.
Contraindications for Ribomustin usage in accordance with product label
Contradictions for rituximab usage in accordance with product label
Clareo Health | Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
